Menlo Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch MNLO and buy or sell other stocks, ETFs, and their options commission-free!About MNLO
Menlo Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause.
CEODavid Domzalski
CEODavid Domzalski
Employees13
Employees13
HeadquartersBridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded2011
Founded2011
Employees13
Employees13
MNLO Key Statistics
Market cap55.86M
Market cap55.86M
Price-Earnings ratio-1.01
Price-Earnings ratio-1.01
Dividend yield—
Dividend yield—
Average volume398.58K
Average volume398.58K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$4.30
52 Week high$4.30
52 Week low$0.9099
52 Week low$0.9099
People also own
Based on the portfolios of people who own MNLO. This list is generated using Robinhood data, and it’s not a recommendation.